B Cell Lymphoma clinical trials

Explore recruiting b cell lymphoma clinical trials.

Recruiting b cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

e-REVRI - A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated with Lenalidomide and Rituximab

France

Phase II and Phase III (Integrated) EU CTIS Study details

VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma

Hungary, Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

France, Italy, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Czechia, Ireland, Hungary, Finland, Denmark, Norway +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients with Diffuse Large B-Cell Lymphoma following First-Line Immunochemotherapy and as Monotherapy or In Combination With Polatuzumab Vedotin in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Spain, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

B Cell Lymphoma trials by city

B Cell Lymphoma in Toronto B Cell Lymphoma in Vancouver B Cell Lymphoma in Montreal B Cell Lymphoma in Calgary B Cell Lymphoma in Edmonton B Cell Lymphoma in Ottawa B Cell Lymphoma in Winnipeg B Cell Lymphoma in Quebec City B Cell Lymphoma in Hamilton B Cell Lymphoma in Kitchener B Cell Lymphoma in London B Cell Lymphoma in Halifax B Cell Lymphoma in New York B Cell Lymphoma in Los Angeles B Cell Lymphoma in Chicago B Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease